microRNAs in kidney diseases: Regulation, therapeutics, and biomarker potential

IF 12 1区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmacology & Therapeutics Pub Date : 2024-08-22 DOI:10.1016/j.pharmthera.2024.108709

Zhiwen Liu , Ying Fu , Mingjuan Yan , Subing Zhang , Juan Cai , Guochun Chen , Zheng Dong

{"title":"microRNAs in kidney diseases: Regulation, therapeutics, and biomarker potential","authors":"Zhiwen Liu , Ying Fu , Mingjuan Yan , Subing Zhang , Juan Cai , Guochun Chen , Zheng Dong","doi":"10.1016/j.pharmthera.2024.108709","DOIUrl":null,"url":null,"abstract":"<div><p>MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression by inhibiting the translation of their specific target messenger RNAs. To date, numerous studies have demonstrated changes in the expression of miRNAs in the kidneys throughout the progression of both acute kidney injury (AKI) and chronic kidney disease (CKD) in both human patients and experimental models. The role of specific microRNAs in the pathogenesis of kidney diseases has also been demonstrated. Further studies have elucidated the regulation of these microRNAs in diseased kidneys. Besides, certain miRNAs are detected in plasma and/or urine in kidney diseases and are potential diagnostic biomarkers. In this review, we provide an overview of recent developments in our understanding of how miRNAs contribute to kidney diseases. We also explore the potential of miRNAs as both biomarkers and therapeutic targets for these conditions, and highlight future research directions.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"262 ","pages":"Article 108709"},"PeriodicalIF":12.0000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725824001293","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression by inhibiting the translation of their specific target messenger RNAs. To date, numerous studies have demonstrated changes in the expression of miRNAs in the kidneys throughout the progression of both acute kidney injury (AKI) and chronic kidney disease (CKD) in both human patients and experimental models. The role of specific microRNAs in the pathogenesis of kidney diseases has also been demonstrated. Further studies have elucidated the regulation of these microRNAs in diseased kidneys. Besides, certain miRNAs are detected in plasma and/or urine in kidney diseases and are potential diagnostic biomarkers. In this review, we provide an overview of recent developments in our understanding of how miRNAs contribute to kidney diseases. We also explore the potential of miRNAs as both biomarkers and therapeutic targets for these conditions, and highlight future research directions.

查看原文本刊更多论文

肾脏疾病中的 microRNAs：调节、治疗和生物标记潜力。

微小 RNA（miRNA）是一种非编码 RNA 小分子，通过抑制其特定目标信使 RNA 的翻译，在调节基因表达方面发挥着至关重要的作用。迄今为止，已有大量研究表明，在人类患者和实验模型中，在急性肾损伤（AKI）和慢性肾病（CKD）的整个进展过程中，肾脏中 miRNA 的表达都会发生变化。特定 microRNA 在肾脏疾病发病机制中的作用也已得到证实。进一步的研究阐明了这些 microRNA 在患病肾脏中的调控作用。此外，在肾脏疾病患者的血浆和/或尿液中检测到某些 miRNA，它们是潜在的诊断生物标志物。在这篇综述中，我们概述了在了解 miRNA 如何导致肾脏疾病方面的最新进展。我们还探讨了 miRNAs 作为这些疾病的生物标志物和治疗靶点的潜力，并强调了未来的研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacology & Therapeutics 医学-药学

CiteScore

23.00

自引率

0.70%

发文量

222

审稿时长

90 days

期刊介绍： Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.